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initiation of heparin anticoagulation before
treatment with factor concentrates in bleed-
ing patients under ECC is controversial,
because the effect of heparin is antithrom-
bin dependent. We recommend the close
monitoring and substitution of antithrom-
bin in conditions with an ongoing activa-
tion of the hemostatic system. Although
there is no evidence from the literature yet,
inhibitor levels (in particular antithrombin)
should be kept within the normal range
before administration of factor concen-
trates to attenuate the procoagulant re-
sponse, possibly resulting in thromboem-
bolic complications.
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Is there an evidence in favor of off-
pump coronary artery bypass?
To the Editor:
We read with interest the report of Mack
and colleagues1 that shows “improved out-
come in coronary artery bypass grafting
with beating-heart techniques.” In the era
of evidence-based medicine and megatri-
als, class A level evidence will remain the
standard tool that forces change of direc-
tion of currently applied surgical proce-
dures, including coronary artery bypass
grafting. We concede that in the absence of
major prospective randomized trials2,3 ret-
rospective studies such as this may contrib-
ute enough evidence to sway the balance in
favor of or against off-pump coronary ar-
tery bypass grafting (OPCAB).
However, we wish to highlight two is-
sues that could have a significant impact on
the conclusions derived from the study.
First, at one point the authors claimed that
the conversion rate was 2.9% and stated
that “these patients were analyzed with the
on-pump group.” Later, however, they re-
ported a conversion rate of 1.6% and sug-
gested that the analysis was performed on
an intent-to-treat basis (that conversions
were analyzed with the OPCAB group).
These conflicting statements require further
clarification. Second, the need for a sub-
group analysis of the cases converted from
OPCAB to an on-pump procedure cannot
be overemphasized. This analysis may pro-
vide the answer to a number of important
questions regarding OPCAB, such as indi-
cations, timing, predictors, and, more im-
portantly, the outcome of conversion in
terms of mortality and morbidity.
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Short esophagi and a long career
To the Editor:
Professor J. Leigh Collis, a prominent sur-
geon, made several contributions to the de-
velopment of the thoracic and cardiac sur-
gery. However, he was immortalized and
known worldwide for his work on gastro-
plasty, originally published in this Journal
46 years ago.1
I contacted by letter the then-90-year-
old Professor Collis, asking for data to be
used in an article concerning the history of
esophageal surgery. I was honored with a
concerned and pleasant reply. After our last
contact, however, I received the grievous
notice that Professor Collis had died on
February 4, 2003.
It is fitting to pay homage to this singu-
lar character in the history of the esopha-
geal surgery in the same Journal that im-
mortalized him.
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Problems with complication rate
analysis
To the Editor:
In a recent issue of this Journal, Grunk-
emeier and Wu1 analyzed complication
rates after bileaflet valve implantation by
means of pooled data and regression anal-
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ysis. Their criticism regarding inappropri-
ate comparison of complication rates for
different valve prostheses is more than jus-
tified. They approached the problem as a
meta-analysis, although the exact criteria
and methodology were not well docu-
mented.
Valid comparison of results with differ-
ent heart valve substitutes is restricted to
controlled, randomized studies. If random-
ized studies are not available, results of
nonrandomized studies may be used to an-
swer clinical questions. However, one
should be extremely careful not to misuse
and misinterpret the data analyzed. The
article to which we are responding is a
potential example of misuse and misinter-
pretation of data taken from the literature,
including the data set of my own group.2
The article has at least four major short-
comings: (1) inconsistent use of linearized
rates, (2) inclusion violations, (3) inade-
quate reflection of follow-up techniques,
and (4) publication bias.
First, in terms of inconsistent use of
linearized rates, for their analysis Grunk-
emeier and Wu1 appear to have included
the early postoperative follow-up period in
the linearized complication rates per pa-
tient year. However, it is not clear whether
this rule was consistently applied. This can
lead to misleading results because of the
elevated and nonlinear rates for both bleed-
ing and thromboembolic complications in
the early postoperative period.3
Second, the study exhibits severe viola-
tions of its own inclusion criteria. For well-
considered reasons, the study results pub-
lished by our group and included in the
regression analysis were explicitly not
based on the American Association for
Thoracic Surgery and Society of Thoracic
Surgeons guidelines for reporting valve-
related morbidity and mortality. Instead,
we used a modified Karnofsky scale, which
does not correspond to these guidelines.
This scale, adapted by us to the special
requirements for the long-term follow-up
after valve replacement, allowed grading of
reported complications2,4 and reporting of
minor bleeding complications. Lack of dif-
ferentiation between the two reporting sys-
tems resulted in severe violation of study
inclusion criteria.
Third, a major problem when analyzing
pooled data is invalid reporting of compli-
cations as a result of inappropriate fol-
low-up techniques.5 The guidelines for re-
porting morbidity and mortality used in the
data sets selected by Grunkemeier and Wu
require reporting of all complications oc-
curring during follow-up. The complete-
ness of reporting is directly related to the
follow-up strategies, such as the time inter-
vals between consecutive follow-up exam-
inations and how the data are gathered.5
Reliable follow-up data that include infor-
mation on transient and reversible events
are most effectively collected with regular
follow-up visits to a specialized outpatient
clinic or by on-line documentation, a strat-
egy first used by my group.2 Indeed, stud-
ies have shown that when, parallel to the
regular follow-up in the outpatient depart-
ment, the same patients were sent question-
naires at 6-, 18-, and 36-month intervals,
about half of the events that were transient
or reversible had been forgotten and there-
fore were not mentioned on the 18- and
36-month questionnaires.5,6 Incomplete
data reporting may be illustrated further by
the following. Of the 21 studies giving full
information with regard to bleeding and
thromboembolism, 4 reported linearized
rates after aortic valve implantation below
the background incidence for the combined
end point of thromboembolism plus bleed-
ing, indicating that proper follow-up tech-
niques were lacking because not even the
background incidence of such complica-
tions in the age-adapted general population
was detected.
Finally, some of the studies included in
the analysis represent atypical situations.
One example is the series published by
Baudet,7 who had patients during the first
postoperative year on antiplatelet medica-
tion only. This series contributed 23 of the
82 valve thromboses (28%, 0.29%/pa-
tient-y) of the St Jude Medical data pool,
compared with an average of 0.13%/pa-
tient-y for all other series. One must not
include such an experimental series in the
analysis of pooled data, because it can lead
to arbitrary and unreliable conclusions.
To conclude, there are three messages
that may come from the article that I crit-
icize here. First, we need refined criteria for
reporting morbidity and mortality after
valve replacement. Cerebral events of un-
known etiology should no longer be
counted as thromboembolism, because
most such patients have cerebral bleeding,
not embolism, when cerebral computed to-
mographic scans are performed. Simple
counting of complications is inappropriate,
because the vast majority of bleeding com-
plications documented during appropriate
follow-up have neither a prognostic impact
nor do they influence quality of life. Re-
porting of morbidity should go along with
grading the severity of the respective com-
plications, as suggested earlier.2
Second, for each study it must be clear
which patients have been included. For
consecutive patients not only the postoper-
ative survivors should be considered but all
patients who underwent surgery (intent-to-
treat analysis). An inept surgeon with a
high intraoperative mortality would in ef-
fect eliminate many patients who would
have to be considered at high risk for post-
operative complications.
Third, in the era of evidence-based
medicine the cardiovascular community
should develop guidelines for the fol-
low-up of patients. A careless cardiologist
unwilling or unable to document potential
complications because of inappropriate fol-
low-up techniques will end up with the best
results (and the combination of an inept
surgeon and a careless cardiologist will al-
ways produce the best results). That may be
the true impact of this article. With regard
to follow-up, the message should be that it
is the careful follow-up documentation of
all complications that ensures the quality of
the study. Sophisticated statistical tech-
niques, no matter how elegant, cannot
make up for deficiencies in this area.
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Reply to the Editor:
We thank Dr Horstkotte for his comments
on our article comparing two heart valves
by means of reports from the literature. In
describing the limitations of such compar-
isons, he gives us another opportunity to
stress the main purpose of our report,
which was to point out precisely these lim-
itations.
Dr Horstkotte found four “shortcom-
ings” and agreed with three “messages” in
our article. The shortcomings were (1) in-
consistent use of linearized rates, (2) inclu-
sion violation, (3) inadequate reflection of
follow-up techniques, and (4) publication
bias.
We attempted to include only late
events in the linearized event rates. Most
reports used in our study considered late
events only, but some used both early and
late events and some were unclear on this
point. We tried to separate those that used
late events from those that used both and
attempted classify those that were unclear
from other clues in the published reports,
but we found this extremely difficult. We
finally decided to use the results as pub-
lished, and we specified this in the Clinical
Material section.
We selected only articles that claimed
to adhere to the American Association for
Thoracic Surgery and Society of Thoracic
Surgeons guidelines for reporting,1,2 as did
Horstkotte and colleagues’ 1993 article,3
which said, “Prosthetic valve related and
anticoagulant-related complications were
reported according to the current guidelines
for reporting morbidity and mortality after
valve replacement surgery.”1 In addition
they used another set of definitions that
included minor bleeding events, but we
used only the major bleeding events, as
recommended by the American Associa-
tion for Thoracic Surgery and Society of
Thoracic Surgeons.2 We did not include
their 1994 article4 in our analysis.
We agree that the completeness of re-
porting complications is directly related to
the follow-up strategy. We only selected
articles with at least 95% follow-up com-
pleteness, evaluated the results as a func-
tion of follow-up completeness, and em-
phasized this issue in the Discussion
section. However, there is no doubt a wide
variation in the use of the word complete. A
thorough evaluation of this variable should
include not just the quantitative (percent-
age) aspect but also a qualitative descrip-
tion of what is meant. Such meanings can
range, for example, from regular office vis-
its with the patient to a phone contact with
a widowed spouse long after the patient has
died.
We attempted to eliminate articles that
did not use universal anticoagulation. We
apparently missed the fact that in Baudet
and associates’ report5 65 patients with
aortic replacements and 10 with mitral re-
placements received aspirin and dipyrid-
amole only for 1 year, and had a higher
incidence of thrombosis and embolism, be-
cause the article itself presented combined
linearized rates. If this article had been
eliminated from our study, however, it
would have not changed the conclusions.
The term publication bias refers to the fact
that the publication of research studies is
nonrandom but depends on the nature and
direction of their findings, as described in
our Discussion section.
We agree completely with the three
“messages” that Dr Horstkotte took from
our article—the needs for (1) refined re-
porting of complications, including grading
of severity, (2) consecutive patients, and
(3) thorough follow-up techniques—and
we again thank him for emphasizing these
points. The purpose of our study was to
stress the limitations of data collection and
definitions, as well as to present refined
statistical methods of valve comparison
used to deal with variability. The short-
comings that Dr Horstkotte mentioned
were exactly what we studied and dis-
cussed in the article.
YingXing Wu, MD
Gary Grunkemeier, PhD
Providence Health System
Portland, Ore
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Safety of bronchoplastic resection
after induction therapy for lung
cancer
To the Editor:
We read with interest the article by Ohta
and colleagues1 concerning the impact of
induction treatment on patients who un-
derwent full sleeve resection. Ohta and
colleagues1 concluded that preoperative
therapy did not significantly affect postop-
erative outcome. The issue of the impact of
the neoadjuvant chemotherapy in patients
with lung cancer is today an object of de-
bate. It has been demonstrated that right
pneumonectomy after induction treatment
is associated with a high risk of postoper-
ative complications,2 and Rendina and col-
leagues3 showed that lung-sparing resec-
tion could reduce the rate of
pneumonectomy and could provide an al-
ternative to a pneumonectomy after induc-
tion treatment.
We published in 2002 our experience
with 27 patients who underwent induction
treatment before lung-sparing resection.4
We had similar results, demonstrating that
chemotherapy or chemoradiotherapy be-
fore surgery did not influence postoperative
outcome. In addition, in our experience
postoperative radiotherapy done for pa-
tients with N2 disease did not influence
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